Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Condition: Colorectal Cancer
MeSH terms: Colorectal Neoplasms
Intervention: standard white light colonoscopy-equivalent to placebo; Methylene Blue MMX tablets
Intervention description: standard white light colonoscopy; 8x25mg methylene blue MMX tablets administered before a colonoscopy
Intervention MeSH terms: Methylene Blue
Phase: Phase 2
Study type: Interventional
Primary purpose: Diagnostic
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 10.0
Sex: All
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      Single Centre, open label assignment phase II clinical study.

      To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to
      endoscopy on double stranded DNA breaks in colonic biopsy samples assessed by histone gamma
      H2AX analysis, compared to control biopsies.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Males or females, aged between 18 and 75.

          -  Outpatients scheduled for screening or surveillance colonoscopy

          -  Subjects must be identified as having the clinical requirement for second colonoscopy
             within 2weeks of the initial colonoscopy.

          -  Women of childbearing potential must use at least one reliable method of
             contraception, be surgically sterilised or be abstinent.

          -  For female subjects, a negative serum pregnancy test is required before Methylene Blue
             MMX® tablets are dispensed to the subject.

          -  Post menopausal patients need to have a period of greater than 1year since last
             menstrual period.

          -  Subjects must be able to comprehend the full nature and purpose of the study,
             including possible risks and side effects.

          -  Subjects must be able to co-operate with the investigator and to comply with the
             requirements of the entire study.

          -  Signed written informed consent prior to inclusion in the study.

        Exclusion Criteria:

          -  No Pregnant or lactating women, or women undergoing fertility treatment.

          -  No previous medical history of, or suspected hypersensitivity to the Methylene Blue
             and/or this formulations ingredients.

          -  No previous medical history of, or suspected hypersensitivity to the PEG based bowel
             cleansing preparation and/or this formulations ingredients.

          -  No previous medical history of gastrointestinal obstruction or perforation, toxic
             megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or
             IV), serious cardiovascular disease.

          -  No ALT, AST, GGT, Bilirubin, Creatinine or Urea greater than 2.5 x the upper limit for
             normal, based on local laboratory testing.

          -  No clinical alarm symptoms or history of anaemia (previously recorded haemoglobin of
             less than 10mg/dL) or frank blood in the stool within the last 30 days prior to
             enrolment.

          -  No known deficiency of glucose-6-phosphate dehydrogenase.

          -  No known deficiency of NADPH reductase.

          -  No treatment within 5 weeks prior to randomisation with Fluoxetine (Prozac).

          -  No concurrent treatment, or previous treatment within 2 weeks with any of the
             prohibited psychiatric medications that may interact with Methylene Blue as listed in
             the Prohibited Medications section; Selective Serotonin Reuptake Inhibitors (SSRI),
             Serotonin-Norepinepherine Reuptake Inhibitors (SNRI's), listed Tricyclic
             anti-depressants or Monoamine oxidase A inhibitors.

          -  No concurrent treatment with anticoagulants, or antiaggregants, inducing an INR > 1.5.

          -  No current enrolment in any other clinical trial, or previous enrolment in a clinical
             trial within the last 30 days.

          -  No other medical condition that in the investigators opinion would make the
             administration of the study drug or procedures hazardous to the subject.

        Exclusion Criteria:

        -